Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success
G Dragneva, P Korpisalo… - Disease models & …, 2013 - journals.biologists.com
Angiogenic therapy, which involves the use of an exogenous stimulus to promote blood
vessel growth, is an attractive approach for the treatment of ischemic diseases. It has been …
vessel growth, is an attractive approach for the treatment of ischemic diseases. It has been …
Evaluation of the clinical relevance and limitations of current pre-clinical models of peripheral artery disease
SM Krishna, SM Omer, J Golledge - Clinical science, 2016 - portlandpress.com
Peripheral arterial disease (PAD) usually results from atherosclerosis and associated
thrombosis and limits blood supply to the lower limbs. Common presenting symptoms …
thrombosis and limits blood supply to the lower limbs. Common presenting symptoms …
[HTML][HTML] Engineered microenvironments for synergistic VEGF–Integrin signalling during vascularization
V Moulisová, C Gonzalez-García, M Cantini… - Biomaterials, 2017 - Elsevier
We have engineered polymer-based microenvironments that promote vasculogenesis both
in vitro and in vivo through synergistic integrin-growth factor receptor signalling. Poly (ethyl …
in vitro and in vivo through synergistic integrin-growth factor receptor signalling. Poly (ethyl …
Co-immobilization of CD133 antibodies, vascular endothelial growth factors, and REDV peptide promotes capture, proliferation, and differentiation of endothelial …
Y Duan, S Yu, P Xu, X Wang, X Feng, Z Mao, C Gao - Acta biomaterialia, 2019 - Elsevier
Capture of endothelial progenitor cells (EPCs) in situ has been considered as a promising
strategy for the rapid endothelialization and long-term patency of artificial blood vessels and …
strategy for the rapid endothelialization and long-term patency of artificial blood vessels and …
Effect of Intramyocardial Administration of Baculovirus Encoding the Transcription Factor Tbx20 in Sheep With Experimental Acute Myocardial Infarction
MR Bauzá, AE López, JA Simonin… - Journal of the …, 2024 - ahajournals.org
Background Gene therapy has been proposed as a strategy to induce cardiac regeneration
following acute myocardial infarction (AMI). Given that Tbx20, a transcription factor of the T …
following acute myocardial infarction (AMI). Given that Tbx20, a transcription factor of the T …
The protective effect of tanshinone IIa on endothelial cells: a generalist among clinical therapeutics
J Feng, L Liu, F Yao, D Zhou, Y He… - Expert Review of Clinical …, 2021 - Taylor & Francis
ABSTRACT Introduction Tanshinone IIa (TSA) has been approved to treat cardiovascular
diseases by the China State Food and Drug Administration. TSA has exhibited a variety of …
diseases by the China State Food and Drug Administration. TSA has exhibited a variety of …
High‐dose plasmid‐mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis‐I). A phase I, open‐label, two‐year follow‐up trial
L Favaloro, M Diez, O Mendiz… - Catheterization and …, 2013 - Wiley Online Library
Objectives We aimed to assess safety and, secondarily, the efficacy of intramyocardial high‐
dose plasmid‐vascular endothelial growth factor (VEGF) 165 (pVEGF165) gene transfer in …
dose plasmid‐vascular endothelial growth factor (VEGF) 165 (pVEGF165) gene transfer in …
The promotion of endothelial cell attachment and spreading using FNIII10 fused to VEGF-A165
S Traub, J Morgner, MM Martino, S Höning, MA Swartz… - Biomaterials, 2013 - Elsevier
Synergy in the downstream signaling pathways of the vascular endothelial growth factor
receptor-2 (VEGFR-2) and the integrin αvβ3 is critical for blood vessel formation. Thus …
receptor-2 (VEGFR-2) and the integrin αvβ3 is critical for blood vessel formation. Thus …
Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia
MA Lijkwan, AA Hellingman, EJ Bos… - Human gene …, 2014 - liebertpub.com
In this study, we target the hypoxia inducible factor-1 alpha (HIF-1-alpha) pathway by short
hairpin RNA interference therapy targeting prolyl hydroxylase-2 (shPHD2). We use the …
hairpin RNA interference therapy targeting prolyl hydroxylase-2 (shPHD2). We use the …
[HTML][HTML] In silico performance analysis of web tools for CRISPRa sgRNA design in human genes
CNN Pedrozo, TM Peralta, FD Olea, P Locatelli… - Computational and …, 2022 - Elsevier
Angiogenic gene overexpression has been the main strategy in numerous vascular
regenerative gene therapy projects. However, most have failed in clinical trials. CRISPRa …
regenerative gene therapy projects. However, most have failed in clinical trials. CRISPRa …